• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: Reviews and advances in the molecular mechanisms of breast cancer.

作者信息

Redfern A, Agarwal V, Alahari S

机构信息

School of Medicine, University of Western Australia, Perth, WA, Australia.

Harry Perkins Institute of Medical Research, Perth, WA, Australia.

出版信息

Front Cell Dev Biol. 2024 Mar 7;12:1380475. doi: 10.3389/fcell.2024.1380475. eCollection 2024.

DOI:10.3389/fcell.2024.1380475
PMID:38516129
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10955372/
Abstract
摘要

相似文献

1
Editorial: Reviews and advances in the molecular mechanisms of breast cancer.社论：乳腺癌分子机制的综述与进展
Front Cell Dev Biol. 2024 Mar 7;12:1380475. doi: 10.3389/fcell.2024.1380475. eCollection 2024.
2
CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review).CDK4/6 抑制剂耐药机制及治疗策略（综述）。
Int J Mol Med. 2022 Oct;50(4). doi: 10.3892/ijmm.2022.5184. Epub 2022 Aug 31.
3
CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer.CDK4/6抑制剂：乳腺癌中的耐药机制及反应性潜在生物标志物
Future Oncol. 2022 Mar;18(9):1143-1157. doi: 10.2217/fon-2021-0842. Epub 2022 Feb 9.
4
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.Elacestrant（RAD1901）在多种对 CDK4/6 抑制剂耐药的 ER+ 乳腺癌模型中表现出抗肿瘤活性。
Breast Cancer Res. 2019 Dec 18;21(1):146. doi: 10.1186/s13058-019-1230-0.
5
Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation.上调的PARP1通过YB-1磷酸化赋予乳腺癌对CDK4/6抑制剂的抗性。
Exp Hematol Oncol. 2023 Nov 30;12(1):100. doi: 10.1186/s40164-023-00462-7.
6
Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition.细胞周期蛋白依赖性激酶抑制及其在乳腺癌中与免疫疗法的交叉：不仅仅是CDK4/6抑制。
Expert Opin Investig Drugs. 2022 Sep;31(9):933-944. doi: 10.1080/13543784.2022.2097067. Epub 2022 Jul 7.
7
Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration.乳腺癌中 CDK4/6 抑制剂反应和耐药的生物标志物：液体活检和 microRNA 探索的提示。
Int J Mol Sci. 2022 Nov 22;23(23):14534. doi: 10.3390/ijms232314534.
8
Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.对细胞周期蛋白依赖性激酶（CDK）4/6抑制剂的耐药性赋予了乳腺癌细胞对其他CDK抑制剂的交叉耐药性，但对化疗药物没有交叉耐药性。
Breast Cancer. 2021 Jan;28(1):206-215. doi: 10.1007/s12282-020-01150-8. Epub 2020 Aug 28.
9
A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.PI3K通路抑制剂与细胞周期通路抑制剂联合用于对抗激素受体阳性乳腺癌的内分泌抵抗：一种基于基因组算法的治疗方法。
Am J Cancer Res. 2018 Dec 1;8(12):2359-2376. eCollection 2018.
10
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.乳腺癌治疗性 CDK4/6 抑制的作用机制。
Semin Oncol. 2017 Dec;44(6):385-394. doi: 10.1053/j.seminoncol.2018.01.006.

本文引用的文献

1
Shaping immune landscape of colorectal cancer by cholesterol metabolites.胆固醇代谢物重塑结直肠癌的免疫景观。
EMBO Mol Med. 2024 Feb;16(2):334-360. doi: 10.1038/s44321-023-00015-9. Epub 2024 Jan 2.
2
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells.TWIST1 上调是逆转转移性腔型乳腺癌细胞对 CDK4/6 抑制剂耐药的潜在靶点。
Int J Mol Sci. 2023 Nov 14;24(22):16294. doi: 10.3390/ijms242216294.
3
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.卡培他滨联合卡培他滨对比安慰剂联合氟维司群治疗激素受体阳性、人表皮生长因子受体 2 阴性晚期乳腺癌的随机、双盲、III 期临床研究
N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131.
4
Androgen receptor function and targeted therapeutics across breast cancer subtypes.雄激素受体功能与乳腺癌各亚型的靶向治疗。
Breast Cancer Res. 2022 Nov 14;24(1):79. doi: 10.1186/s13058-022-01574-4.
5
Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq.基于 RNA-seq 的帕博西尼耐药三阴性乳腺癌差异基因表达分析。
Breast Cancer Res Treat. 2021 Apr;186(3):677-686. doi: 10.1007/s10549-021-06127-5. Epub 2021 Feb 18.
6
Controversies around epithelial-mesenchymal plasticity in cancer metastasis.癌症转移中上皮-间充质可塑性的争议。
Nat Rev Cancer. 2019 Dec;19(12):716-732. doi: 10.1038/s41568-019-0213-x. Epub 2019 Oct 30.
7
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.采用联合免疫疗法治疗免疫热、改变和冷肿瘤的方法。
Nat Rev Drug Discov. 2019 Mar;18(3):197-218. doi: 10.1038/s41573-018-0007-y.
8
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.浸润淋巴细胞与不同亚型乳腺癌患者预后的关系：新辅助化疗治疗 3771 例患者的汇总分析
Lancet Oncol. 2018 Jan;19(1):40-50. doi: 10.1016/S1470-2045(17)30904-X. Epub 2017 Dec 7.
9
CDK4/6 inhibition triggers anti-tumour immunity.细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制可触发抗肿瘤免疫。
Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16.
10
Emerging functional roles of nuclear receptors in breast cancer.核受体在乳腺癌中的新兴功能作用
J Mol Endocrinol. 2017 Apr;58(3):R169-R190. doi: 10.1530/JME-16-0082. Epub 2017 Jan 13.